Fig. 4From: Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)Percentage of responders at EoT. a Achieving a ≥ 10-point improvement in OAB-q Symptom Bother score, Total HRQoL, and OAB-q HRQoL subscales; b Achieving an OAB-S Medication Tolerability score ≥ 90Back to article page